The current financial score of Upstream Bio Inc is 6.56. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 773.00K, representing a year-over-year decrease of 17.50%, while its net profit experienced a year-over-year decrease of 0.66%.
The current valuation score of Upstream Bio Inc is 7.05. Its current P/E ratio is -1.78, which is 0.00% below the recent high of -1.78 and -1034.32% above the recent low of -20.21.
The current earnings forecast score of Upstream Bio Inc is 7.75. The average price target is 34.00, with a high of 75.00 and a low of 15.00.
The current price momentum score of Upstream Bio Inc is 5.08. Currently, the stock price is trading between the resistance level at 6.54 and the support level at 4.39, making it suitable for range-bound swing trading.
The current institutional shareholding score of Upstream Bio Inc is 10.00. The latest institutional shareholding proportion is 103.41%, representing a quarter-over-quarter increase of 11.33%.
The current risk assessment score of Upstream Bio Inc is 4.37. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.